Mugwort and Moxibustion: What the Clinical Trials Actually Show

Moxibustion is mugwort's one claim to a real randomized-trial literature, and the trials are genuinely worth reading — including the ones that failed. But before crediting any of that evidence to Artemisia vulgaris specifically, there is a question almost nobody asks: what plant is actually smoldering in the stick? The honest answer is that most commercial moxa, in most of the trials below, is manufactured from a closely related but botanically distinct East Asian species, and the clinical literature is remarkably casual about the difference.

Table of Contents

  1. What Actually Happens When Moxa Burns
  2. The Species Question: Is Clinical Moxa Even Artemisia vulgaris?
  3. Breech Presentation: The Positive Trials
  4. Breech Presentation: The Negative Trial, and What Cochrane Actually Concludes
  5. The One Trial That Named the Species — and Tested Something Different
  6. Beyond Breech: Hypertension, Dysmenorrhea, and Other Indications
  7. Moxa Smoke and Contact Safety
  8. What This Means for Someone Considering Moxibustion
  9. Key Research Papers
  10. Connections

What Actually Happens When Moxa Burns

The Mugwort hub page covers the ritual and traditional-medicine framing of moxibustion — "warming the channels," adding yang, the pairing with acupuncture that gives the Chinese term for the whole discipline (zhēnjiǔ, "needle-moxa") its name. This page sets tradition aside and asks a narrower, more answerable question: what does the actual randomized-trial evidence say, and about which plant?

Stripped of theory, moxibustion is radiant heat plus aromatic smoke delivered to a point on the skin, usually for ten to twenty minutes, either directly (a small cone burned close to or on the skin) or indirectly (a rolled stick held near the point, or a bead of moxa smoldering on the handle of an inserted acupuncture needle). The felted material that burns — "moxa wool" — is made by drying, grinding, and repeatedly sieving mugwort leaves until only the fine, combustible fiber remains.

Back to Table of Contents

The Species Question: Is Clinical Moxa Even Artemisia vulgaris?

This is the point that almost every popular article on moxibustion — and a fair number of the trial papers themselves — glosses over, and it matters enough to lead with. Commercial moxa wool, including the overwhelming majority of what is sold and used in acupuncture clinics worldwide, is manufactured from Artemisia argyi ("Ai Ye," 艾叶), a East Asian species distinct from the European Artemisia vulgaris this page is otherwise about. The town of Qichun in Hubei province is even geographically associated with premium argyi moxa production the way Champagne is associated with sparkling wine, and a 2010 Chinese analysis tracked how argyi's chemical composition and moxa-wool quality shift by harvest year and processing ratio specifically for that supply chain.[11] Modern combustion-chemistry work profiling what compounds are actually released when moxa burns has likewise been done specifically on Artemisia argyi, not vulgaris.[14]

Against that backdrop, it is genuinely striking how loosely the English-language clinical literature uses the name "Artemisia vulgaris." A 2014 systematic review of moxibustion for hypertension is titled, without any apparent unease, "Effectiveness of Stimulation of Acupoint KI 1 by Artemisia vulgaris (the Japanese name is moxa)" — using the European binomial as a generic label for an East Asian therapeutic product.[6] A 2016 Danish randomized trial of moxibustion for breech presentation states flatly, in its own introduction, that "moxibustion is heat generated by a burning stick containing the herb Artemisia vulgaris"[4] — and it is very unlikely that a Danish maternity clinic in 2013–2015 was importing hand-processed European mugwort rather than buying commercial moxa sticks off the shelf, which almost certainly means argyi. None of the major breech-presentation trials discussed below report verifying the species of their moxa sticks by chromatography, DNA barcoding, or any other method — they report a brand or a supplier, if they report anything about the product at all. This is exactly the situation the site's evidence doctrine warns about elsewhere: a marker-compound or a common name is not the same thing as a verified identity, and "Artemisia vulgaris" has become a loose English gloss for "the plant moxa is made from" rather than a checked botanical fact.

The two species are close relatives and share core chemistry — both carry thujone, 1,8-cineole, camphor, and overlapping sesquiterpene lactones — which is presumably why the substitution has drawn so little scrutiny; the smoke and the warmth would feel similar either way. But "similar chemistry" is not "the same evidence." This page tries to handle that honestly: trials that explicitly and correctly name Artemisia vulgaris are flagged as such: everything else below is evidence for "the traditional moxa preparation" in general, which in practice usually means Artemisia argyi, not proof of an effect specific to the species covered by the rest of this site.

Back to Table of Contents

Breech Presentation: The Positive Trials

The best-known and most rigorously studied use of moxibustion anywhere is turning a breech (feet- or bottom-first) baby to a head-down position before birth, by burning moxa near acupuncture point BL67 (Zhiyin), at the outer corner of the little toe.

The landmark trial is Cardini and Weixin's 1998 JAMA study, run in two hospitals in Jiangxi Province, China — the Women's Hospital of Jiangxi Province in Nanchang and Jiujiang Women's and Children's Hospital — in 260 primigravidas at 33 weeks' gestation with confirmed breech presentation.[1] Half received moxa stick stimulation at BL67 for about fifteen minutes, once or twice daily, for up to seven days; the rest did not. Moxa-treated fetuses showed markedly increased movement in the first treatment session (48 versus 35 movements per hour), and by 35 weeks 75% of the moxa group had turned head-down against 48% of controls — a large, clinically meaningful difference from a trial conducted, given the hospital setting and era, almost certainly with commercial Chinese moxa, i.e. Artemisia argyi.

A second positive trial, run in Spanish and Portuguese primary-care settings by Vas and colleagues in 2013, found a similar benefit in a multicentre randomized design comparing moxibustion to usual care for non-vertex presentation, again without reporting species verification of the moxa product used.[2] A separate cost-effectiveness analysis built on trial data of this kind concluded that adding moxibustion to standard care is a low-cost way to reduce the need for external cephalic version and cesarean delivery for breech presentation, which is a real and useful finding about the intervention as clinically practiced — again, using whatever moxa product primary-care clinics in that setting actually stock.[8]

Back to Table of Contents

Breech Presentation: The Negative Trial, and What Cochrane Actually Concludes

The positive trials are not the whole story, and presenting only them would be exactly the kind of cherry-picking this site's evidence doctrine argues against. A 2016 Danish randomized trial by Bue and Lauszus, registered on ClinicalTrials.gov (NCT02251886), enrolled 200 women at 33 weeks with singleton breech presentation and randomized them to daily moxibustion for two weeks or no moxibustion.[4] The result was a flat null: 74% of the treated group and 46% of controls still showed breech position after the trial period in the raw numbers, but once parity was accounted for the risk ratio was 1.05 (95% CI 0.8–1.38) — no significant effect of moxibustion on correcting breech position, in either nulliparous or parous women. This is a genuinely large, well-registered negative trial, and it deserves the same weight as the positive ones rather than being treated as an outlier to explain away.

The Cochrane systematic review of this literature, most recently updated in 2023 by Coyle, Smith, and Peat, pools these and other trials and lands where a body of evidence with real positive results and a real large negative result should land: cautiously.[3] Moxibustion — usually combined with acupuncture or added to usual care — may reduce the number of non-cephalic births and the need for external cephalic version, but the certainty of that evidence is rated low, and the trials it pools vary considerably in design, moxa protocol, and (as far as can be told from the published methods) moxa product. A study on factors affecting how well moxibustion performs as a preliminary treatment before external cephalic version reaches a similarly qualified conclusion: some women respond, many do not, and predicting which is which in advance is not yet reliable.[9]

The fair summary, matching the Mugwort hub page's own framing: moxibustion for breech presentation is plausible, low-risk under professional supervision, and the single best-studied use of any mugwort-plant preparation in humans — but "best-studied" here means "studied enough to know the answer is genuinely mixed," not "proven."

Back to Table of Contents

The One Trial That Named the Species — and Tested Something Different

There is exactly one clinical trial in this literature that both explicitly used the term "Artemisia vulgaris" as a controlled comparison arm and tested something other than breech correction: a 2015 Korean cross-over, single-blind randomized study by Go and colleagues, published in the Journal of Traditional Chinese Medicine.[5] Forty healthy adults (38 completed) received, in cross-over order, moxa cones labeled as Artemisia vulgaris and separately charcoal moxa, applied at the Zhongwan (CV 12) acupoint for thirty minutes, with skin temperature at three points measured afterward by infrared thermal imaging.

The result is a useful piece of honesty about what moxibustion physically does. Neither preparation produced a statistically significant rise in skin temperature at the treated point. Artemisia vulgaris moxa did produce a significant change in the temperature difference between two nearby points, and charcoal moxa produced a different pattern of temperature differences by sex — interesting for acupuncture-point physiology, but this is not evidence that mugwort moxa reliably "warms" the body in the way the traditional framing implies. The authors themselves concluded that larger trials are needed before drawing conclusions about moxibustion's thermal effect. What this trial is good for on this page is narrower and more useful: it is the one place in the moxibustion literature where the plant is both named correctly and (plausibly, given the Korean cross-over pilot design) actually verified as the labeled product, rather than a loose English gloss for whatever commercial moxa was on hand.

Back to Table of Contents

Beyond Breech: Hypertension, Dysmenorrhea, and Other Indications

Breech correction is moxibustion's most famous trial, but far from its only one. A 2014 systematic review and meta-analysis by Yang and colleagues pooled randomized trials of moxibustion at acupoint KI 1 (Yongquan) added to antihypertensive medication for essential hypertension, finding a modest additional reduction in systolic blood pressure (weighted mean difference −4.91 mmHg) but no significant effect on diastolic pressure, compared to medication alone.[6] That is a real, quantified, adjunct-only signal — moxibustion plus drugs beating drugs alone by a small margin on one of two blood-pressure numbers — not evidence that moxibustion can substitute for antihypertensive therapy.

Moxibustion for primary dysmenorrhea (menstrual pain) has its own substantial trial base; a 2026 network meta-analysis in the Chinese-language journal Zhongguo Zhen Jiu compares different moxibustion protocols against each other specifically for this indication, one of dozens of trials PubMed indexes under "moxibustion" and "dysmenorrhea."[10] This site cannot verify the fine-grained results of a Chinese-language network meta-analysis firsthand, but its existence is itself informative: dysmenorrhea, alongside breech presentation, cancer-supportive care, and knee osteoarthritis, is one of the handful of indications where moxibustion has moved well beyond single small trials into meta-analytic territory — a trial volume no other mugwort preparation on this site comes close to. An older, smaller line of animal research also tested moxibustion at abdominal points for preventing NSAID-induced gastric lesions in rats, a mechanistic curiosity rather than a clinical claim, but consistent with the broader pattern of moxibustion research reaching into gastrointestinal as well as musculoskeletal and reproductive territory.[7]

The consistent thread across all of this trial volume, positive and negative alike, is that essentially none of it verifies which Artemisia species was actually burned. The clinical question being answered is "does moxibustion, as practiced with whatever moxa a given clinic sources, do X" — a real and useful question, but a different one from "does Artemisia vulgaris do X."

Back to Table of Contents

Moxa Smoke and Contact Safety

Two safety findings are worth stating plainly, separate from the internal-use cautions covered on the hub page and the essential-oil deep-dive. First, moxibustion is not risk-free even used exactly as intended: a 2021 case report in Contact Dermatitis documents allergic contact dermatitis caused directly by a traditional Chinese medicine moxibustion treatment — a real, if uncommon, adverse reaction to skin contact with burning or recently-burned moxa, distinct from the pollen and food-allergy cross-reactivity discussed elsewhere on this site.[13] Second, modern analytical chemistry has begun characterizing exactly what compounds moxa smoke releases during combustion, using Artemisia argyi as the study material — again the East Asian species, not vulgaris — which at least means the smoke-composition safety data that exists corresponds to the plant actually being burned in most clinics.[14] Ventilation during treatment is a reasonable precaution on general principle, given that any smoke carries particulate and volatile-compound exposure; this site is not aware of dedicated human trial data quantifying that specific risk for moxibustion practitioners at typical clinical exposure levels, and does not claim more precision than that.

Back to Table of Contents

What This Means for Someone Considering Moxibustion

Three things can be true at once here, and the honest picture needs all three. Moxibustion has the largest and most methodologically serious clinical trial literature of any mugwort-plant preparation on this site, including a genuine negative trial that keeps the positive results honest. That evidence, taken as a whole, supports "plausible and low-risk, not proven" for breech correction, and a similarly qualified "small adjunct benefit" for blood pressure — not dramatic claims, but real ones, resting on real randomized trials. And almost none of that trial evidence can be confidently attributed to the specific species, Artemisia vulgaris, that the rest of this site covers, because the commercial product actually used in most clinics and most trials is very likely the related East Asian species Artemisia argyi, mislabeled or unlabeled throughout much of the literature. None of this is a reason to avoid moxibustion, which remains a low-risk, externally-applied, professionally-supervised intervention with real if modest trial support. It is a reason to be precise about what that trial support is actually evidence for.

Back to Table of Contents

Key Research Papers

  1. Cardini F, Weixin H. Moxibustion for correction of breech presentation: a randomized controlled trial. JAMA. 1998;280(18):1580-1584. — PubMed: Cardini breech moxibustion 1998 — the landmark positive trial; conducted in Chinese hospitals, moxa species not verified.
  2. Vas J, Aranda-Regules JM, Modesto M, et al. Using moxibustion in primary healthcare to correct non-vertex presentation: a multicentre randomised controlled trial. Acupuncture in Medicine. 2013;31(1):31-38. — PubMed: Vas non-vertex moxibustion 2013 — second positive multicentre trial, Spain/Portugal.
  3. Coyle ME, Smith CA, Peat B. Cephalic version by moxibustion for breech presentation. Cochrane Database of Systematic Reviews. 2023;(5):CD003928. — PubMed: Cochrane cephalic version moxibustion — the up-to-date systematic review: low-certainty, mixed evidence.
  4. Bue L, Lauszus FF. Moxibustion did not have an effect in a randomised clinical trial for version of breech position. Danish Medical Journal. 2016;63(2):A5199. — PubMed: Bue Lauszus negative breech trial — large (N=200) negative RCT; abstract explicitly names Artemisia vulgaris as the moxa plant without verification.
  5. Go HY, Lee JA, Park S, et al. Comparative effects of artemisia vulgaris and charcoal moxa stimulating Zhongwan (CV 12) on body temperature in healthy participants: a cross-over single-blind randomized study. Journal of Traditional Chinese Medicine. 2015;35(5):551-557. — PubMed: Go Artemisia vulgaris Zhongwan moxa — the one trial that both names and pilot-tests Artemisia vulgaris moxa specifically; found no significant temperature rise.
  6. Yang X, Xiong X, Yang G, Wang J. Effectiveness of Stimulation of Acupoint KI 1 by Artemisia vulgaris (Moxa) for the Treatment of Essential Hypertension: A Systematic Review of Randomized Controlled Trials. Evidence-Based Complementary and Alternative Medicine. 2014;2014:187484. — PubMed: Artemisia vulgaris KI1 hypertension moxa — modest adjunct systolic-only benefit; title itself uses "Artemisia vulgaris" as a generic gloss for moxa.
  7. Freire AO, Sugai GC, Blanco MM, Tabosa A. Effect of moxibustion at acupoints Ren-12 (Zhongwan), St-25 (Tianshu), and St-36 (Zuzanli) in the prevention of gastric lesions induced by indomethacin in Wistar rats. Digestive Diseases and Sciences. 2005;50(2):366-374. — PubMed: moxibustion indomethacin gastric lesions — animal data only; illustrates moxibustion's broader research footprint.
  8. Cost effectiveness of using moxibustion to correct non-vertex presentation. Acupuncture in Medicine. 2015. — PubMed: moxibustion cost effectiveness non-vertex — health-economic analysis built on the positive-trial evidence base.
  9. Factors affecting the success of moxibustion in the management of a breech presentation as a preliminary treatment to external cephalic version. Midwifery. 2009. — PubMed: moxibustion external cephalic version factors — predicting response is not yet reliable.
  10. Different moxibustion therapies for primary dysmenorrhea: a network meta-analysis. Zhongguo Zhen Jiu (Chinese Acupuncture & Moxibustion). 2026. — PubMed: moxibustion dysmenorrhea network meta-analysis — Chinese-language; cited for existence/volume of trial base, not for verified fine-grained results.
  11. Jin R, Yu MM, Zhao BX, Fu XT. [Analysis on chemical compositions of Artemisia Argyi from Qichun of different years and moxa wool refined in different proportions]. Zhongguo Zhen Jiu (Chinese Acupuncture & Moxibustion). 2010;30(5):389-392. — PubMed: Artemisia argyi Qichun moxa wool — direct evidence that commercial moxa-wool chemistry research targets argyi, not vulgaris.
  12. Shao Y, Zhou Y, Wan J, Zhu Z. Using terahertz spectroscopy to quantify bioactive flavonoids in Moxa Wool as predictor of rheumatoid arthritis treatment outcomes. Phytomedicine. 2024;133:155927. — PubMed: moxa wool terahertz flavonoids — modern processed-product chemistry, not species-labeled as vulgaris.
  13. Xie Z, Zhang Y, Yang YT, Su Y. Allergic contact dermatitis caused by a traditional Chinese medicine treatment - moxibustion. Contact Dermatitis. 2021;84(2):127-130. — PubMed: moxibustion contact dermatitis — skin-contact adverse reaction case report.
  14. Ma FL, Liu JN, Wang XC, Ma GM. A novel comprehensive strategy for high-thoroughly studying released compounds during the combustion process of herbs. A case study for Artemisia argyi Levl. et Vant. Journal of Chromatography A. 2024;1716:464653. — PubMed: Artemisia argyi combustion compounds — moxa-smoke chemistry research explicitly on argyi.

Back to Table of Contents

Connections

Back to Table of Contents